Advances in the surgical management of liver malignancies

Cancer Journal

Volumn 10, Issue 2, 2004, Pages 74-87

  Pawlik, Timothy M ^a,b   Scoggins, Charles R ^a,b   Thomas, Melanie B ^a,b   Vauthey, Jean Nicolas ^a,b  

^a Department of Surgical Oncology ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Fibrolamellar carcinoma; Fibrosis; Hepatitis; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Resection; Review; Transplantation

Indexed keywords

ARTIFICIAL EMBOLISM; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MORBIDITY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; UNITED STATES; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CANCER STAGING; DECISION TREE; INTRAHEPATIC BILE DUCT; ORGAN SIZE; PATHOLOGY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DECISION TREES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASM STAGING; ORGAN SIZE;

EID: 4544333808     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200403000-00003     Document Type: Review

References (141)

1. Bosch F. Global epidemiology of hepatocellular carcinoma. In: Tabor E, ed. Liver Cancer. New York: Churchill Livingstone, 1997:13-28.
2. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
4. Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
5. McKean-Cowdin R, Feigelson HS, Ross RK et al. Declining cancer rates in the 1990s. J Clin Oncol 2000;18:2258-2268.
6. Barbara L, Benzi G, Gaiani S et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992;16:132-137.
7. Ezaki T, Stansby G, Hobbs K. Regional differences in hepatocellular carcinoma and its surgical treatment. HPB Surg 1991;4:121-128.
8. Simonetti RG, Camma C, Fiorello F et al. Hepatocellular carcinoma: a worldwide problem and the major risk factors. Dig Dis Sci 1991;36:962-972.
9. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15 [suppl]:E25-30.
10. Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:1356-1361.
11. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87-107, vi.
12. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999;31[suppl 11:9-16.
13. Di Bisceglie AM, Cariihers RL, Jr., Gores GJ. Hepatocellular carcinoma. Hepatology 1998;28:1161-1165.
14. Esnaola N, Mirza N, Lauwers G et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg 2003;238:711-719.
15. Bilimoria M, Lauwers G, Doherty D. Underlying liver disease but not tumor factors predict long-term survival after hepatic resection of hepatocellular carcinoma. Arch Surg 2001;136:528-535.
16. Yamamoto J, Kosuge T, Takayama T. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996;83:1219-1222.
17. Nagasue N, Uchida M, Makino Y et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993;105:488-494.
18. Kosuge T, Makuuchi M, Takayama T. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology 1993;40:328-332.
19. Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536.
20. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918-928.
21. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
22. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma: the Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840-845.
23. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
24. Cance WG, Stewart AK, Menck HR. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996. Cancer 2000;88:912-920.
25. Liver including intrahepatic bile ducts. In: Greene FL, Page DL, Fleming ID et al, eds. American Joint Committee on Cancer Staging Manual. New York: Springer, 2002:131-144.
26. Ikai I, Yamamoto Y, Yamamoto N et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin North Am 2003;12:65-75.
27. Tsai TJ, Chau GY, Lui WY et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000;127:603-608.
28. Vauthey JN, Klimstra D, Franceschi D et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995;169:28-34; discussion 34-25.
29. Sasaki Y, Imaoka S, Masutani S et al. Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma. Surgery 1992;112:515-521.
30. Jwo SC, Chiu JH, Chau GY et al. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology 1992;16:1367-1371.
31. Chen MF, Hwang TL, Jeng LB et al. Postoperative recurrence of hepatocellular carcinoma: two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg 1994;129:738-742.
32. Okada S, Shimada K, Yamamoto J et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994;106:1618-1624.
33. Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10-24.
34. Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin North Am 2003;12:35-50, viii.
35. Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994:2272-2780.
36. Tsuzuki T, Sugioka A, Ueda M et al. Hepatic resection for hepatocellular carcinoma. Surgery 1990;107:511-520.
37. Farges O, Malassagne B, Flejou JF et al. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg 1999;229:210-215.
38. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
39. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
40. Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018-1022.
41. Bosch J, Mastai R, Kravetz D et al. Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis 1986;6:309-317.
42. Starzl TE, Putnam CW, Groth CG et al. Alopecia, ascites, and incomplete regeneration after 85 to 90 per cent liver resection. Am J Surg 1975;129:587-590.
43. Soyer P, Roche A, Elias D et al. Hepatic metastases from colorectal cancer: influence of hepatic volumetric analysis on surgical decision making. Radiology 1992;184:695-697.
44. Kubota K, Makuuchi M, Kusaka K et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997;26:1176-1181.
45. Vauthey JN, Chaoui A, Do KA et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000;127:512-519.
46. Vauthey JN, Abdalla EK, Doherty DA et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002;8:233-240.
47. Hemming AW, Reed AI, Howard RJ et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003;237:686-693.
48. Abdalla EK, Barnett CC, Doherty D et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675-680; discussion 680-671.
49. Shirabe K, Shimada M, Gion T et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999;188:304-309.
50. Panis Y, McMullan DM, Emond JC. Progressive necrosis after hepatectomy and the pathophysiology of liver failure after massive resection. Surgery 1997;121:142-149.
51. Yigitler C, Farges O, Kianmanesh R et al. The small remnant liver after major liver resection: how common and how relevant? Liver Transpl 2003;9:518-525.
52. Shoup M, Gonen M, D'Angelica M et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7:325-330.
53. Madoff DC, Hicks ME, Abdalla EK et al. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness-study in 26 patients. Radiology 2003;227:251-260.
54. Uesaka K, Nimura Y, Nagino M. Changes in hepatic lobar function after right portal vein embolization: an appraisal by biliary indocyanine green excretion. Ann Surg 1996;223:77-83.
55. Farges O, Belghiti J, Kianmanesh R et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217.
56. Nagino M, Nimura Y, Hayakawa N et al. Logistic regression and discriminant analyses of hepatic failure after liver resection for carcinoma of the biliary tract. World J Surg 1993;17:250-255.
57. Wakabayashi H, Okada S, Maeba T et al. Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers: a preliminary report. Surg Today 1997;27:403-410.
58. Chiu NT, Sun YN, Chou YL et al. Measurement of organ volume by single photon emission computed tomography. Nucl Med Commun 1994;15:871-877.
59. Miki K, Kubota K, Inoue Y et al. Receptor measurements via Tc-GSA kinetic modeling are proportional to functional hepatocellular mass. J Nucl Med 2001;42:733-737.
60. Nagorney DM, van Heerden JA, Ilstrup DM et al. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989;106:740-748; discussion 748-749.
61. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg 1990;211:277-287.
62. Lai EC, Ng IO, Ng MM et al. Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology 1990;11:815-818.
63. Makuuchi M, Kosuge T, Takayama T et al. Surgery for small liver cancers. Semin Surg Oncol 1993;9:298-304.
64. Fan ST, Lo CM, Liu CL et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229:322-330.
65. Jarnagin WR, Gonen M, Fong Y et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397-406; discussion 406-407.
66. Wei AC, Poon RT, Fan ST et al. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 2003;90:33-41.
67. Johnson M, Mannar R, Wu AV. Correlation between blood loss and inferior vena caval pressure during liver resection. Br J Surg 1998;85:188-190.
68. Takayama T, Makuuchi M, Kubota K et al. Randomized comparison of ultrasonic vs clamp transection of the liver. Arch Surg 2001;136:922-928.
69. Iwatsuki S, Gordon RD, Shaw BW, Jr. et al. Role of liver transplantation in cancer therapy. Ann Surg 1985;202:401-407.
70. O'Grady JG, Polson RJ, Rolles K et al. Liver transplantation for malignant disease: results in 93 consecutive patients. Ann Surg 1988;207:373-379.
71. Bismuth H, Chiche L, Adam R et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151.
72. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
73. Llovet JM, Bruix J, Fuster J et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998;27:1572-1577.
74. Colella G, De Carlis L, Rondinara GF et al. Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation? Transplant Proc 1997;29:492-494.
75. Wudel L, Chapman W. Indications and limitations of liver transplantation for hepatocellular carcinoma. Surg Oncol Clin North Am 2003;12:77-90.
76. Chung SW, Toth JL, Rezieg M et al. Liver transplantation for hepatocellular carcinoma. Am J Surg 1994;167:317-321.
77. Dodson SF, de Vera ME, Bonham CA et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000;6:434-439.
78. Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000;70:809-815.
79. Hemming AW, Cattral MS, Reed AI et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001;233:652-659.
80. Ghobrial RM, Farmer DG, Baquerizo A et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-831; discussion 831-823.
81. Feray C, Caccamo L, Alexander GJ et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C: European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
82. Testa G, Crippin JS, Netto GJ et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000;6:553-561.
83. Hanazaki K, Kajikawa S, Shimozawa N et al. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology 2002;49:311-316.
84. Saxena R, Ye MQ, Emre S et al. De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. Liver Transpl Surg 1999;5:81-82.
85. Livraghi T, Festi D, Monti F et al. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 1986;161:309-312.
86. Ebara M, Ohto M, Sugiura N et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: study of 95 patients. J Gastroenterol Hepatol 1990;5:616-626.
87. Castells A, Bruix J, Bru C et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993;18:1121-1126.
88. Orlando A, D'Antoni A, Camma C et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am J Gastroenterol 2000;95:2921-2927.
89. Giorgio A, Tarantino L, de Stefano G et al. Ultrasound-guided percutaneous ethanol injection under general anesthesia for the treatment of hepatocellular carcinoma on cirrhosis: long-term results in 268 patients. Eur J Ultrasound 2000;12:145-154.
90. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256-1261.
91. Trinchet JC, Mathieu D, Beaugrand M. [Is there a place for arterial chemoembolization of the liver in the treatment for hepatocellular carcinoma?]. Gastroenterol Clin Biol 1995;19:967-969.
92. Pelletier G, Roche A, Ink O et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-184.
93. Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-1583.
94. Bismuth H, Morino M, Sherlock D et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992;163:387-394.
95. Ryder SD, Rizzi PM, Metivier E et al. Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut 1996;38:125-128.
96. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
97. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
98. Curley SA, Izzo F, Ellis LM et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232:381-391.
99. Leung TW, Tang AM, Zee B et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421-427.
100. Savage CR, Jr., Inagami T, Cohen S. The primary structure of epidermal growth factor. J Biol Chem 1972;247:7612-7621.
101. Hoffmann B, Piasecki A, Paul D. Proliferation of fetal rat hepatocytes in response to growth factors and hormones in primary culture. J Cell Physiol 1989;139:654-662.
102. Hoffmann B, Paul D. Basic fibroblast growth factor and transforming growth factor-alpha are hepatotrophic mitogens in vitro. J Cell Physiol 1990;142:149-154.
103. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993;62:453-481.
104. Morimitsu Y, Hsia CC, Kojiro M et al. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 1995;26:1126-1132.
105. Inui Y, Higashiyama S, Kawata S et al. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 1994;107:1799-1804.
106. Hisaka T, Yano H, Haramaki M et al. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol 1999;14:453-460.
107. Nagorney DM, Adson MA, Weiland LH et al. Fibrolamellar hepatoma. Am J Surg 1985;149:113-119.
108. Soreide O, Czerniak A, Bradpiece H et al. Characteristics of fibrolamellar hepatocellular carcinoma: a study of nine cases and a review of the literature. Am J Surg 1986;151:518-523.
109. Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J et al. Fibrolamellar hepatocellular carcinoma in Mexican patients. Pathol Oncol Res 2002;8:133-137.
110. Hemming AW, Langer B, Sheiner P et al. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg 1997;1:342-346.
111. El-Gazzaz G, Wong W, El-Hadary MK et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int 2000;13[suppl 1]:5406-409.
112. Patt YZ, Hassan MM, Lozano RD et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21:421-427.
113. Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002;17:401-405.
114. McLarney JK, Rucker PT, Bender GN et al. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics 1999;19:453-471.
115. Caseiro-Alves F, Zins M, Mahfouz AE et al. Calcification in focal nodular hyperplasia: a new problem for differentiation from fibrolamellar hepatocellular carcinoma. Radiology 1996;198:889-892.
116. Katzenstein HM, Krailo MD, Malogolowkin MH et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003;97:2006-2012.
117. Ringe B, Wittekind C, Weimann A et al. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet 1992;175:299-305.
118. Busuttil RW, Farmer DG. The surgical treatment of primary hepatobiliary malignancy. Liver Transpl Surg 1996;2:114-130.
119. Ichikawa T, Federle MP, Grazioli L et al. Fibrolamellar hepatocellular carcinoma: pre- and posttherapy evaluation with CT and MR imaging. Radiology 2000;217:145-151.
120. Payne CM, Nagle RB, Paplanus SH et al. Fibrolamellar carcinoma of liver: a primary malignant oncocytic carcinoid? Ultrastruct Pathol 1986;10:539-552.
121. Hiramatsu K, Okamoto K, Uesaka K el al. Surgical management for lymph node recurrence of resected fibrolamellar hepatocellular carcinoma: a case report. Hepatogastroenterology 1999;46:1160-1163.
122. Epstein BE, Pajak TF, Haulk TL et al. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol 1999;22:22-28.
123. Pinna AD, Iwatsuki S, Lee RG et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 1997;26:877-883.
124. Neuhaus P, Jonas S, Bechstein WO. Hepatoma of the liver-resection or transplantation? Langenbecks Arch Surg 2000;385:171-178.
125. Belamaric J. Intrahepatic bile duct carcinoma and C. sinensis infection in Hong Kong. Cancer 1973;31:468-473.
126. Chen PH, Lo HW, Wang CS et al. Cholangiocarcinoma in hepatolithiasis. J Clin Gastroenterol 1984;6:539-547.
127. Rosen CB, Nagorney DM. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 1991;11:26-30.
128. Kobayashi M, Ikeda K, Saitoh S et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000;88:2471-2477.
129. Sano T, Kamiya J, Nagino M et al. Macroscopic classification and preoperative diagnosis of intrahepatic Cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 1999;6:101-107.
130. Inoue K, Makuuchi M, Takayama T et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type Cholangiocarcinoma. Surgery 2000;127:498-505.
131. Itamoto T, Asahara T, Katayama K et al. Hepatic resection for intrahepatic Cholangiocarcinoma: relation to gross tumor morphology. Hepatogastroenterology 2001;48:1129-1133.
132. Hirohashi K, Uenishi T, Kubo S et al. Histologic bile duct invasion by a mass-forming intrahepatic Cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2002;9:233-236.
133. Chu KM, Lai EC, Al-Hadeedi S et al. Intrahepatic cholangiocarcinoma. World J Surg 1997;21:301-305; discussion 305-306.
134. Uenishi T, Hirohashi K, Kubo S et al. Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic Cholangiocarcinoma. Br J Surg 2001;88:969-974.
135. Weimann A, Vamholt H, Schlitt HJ et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg 2000;87:1182-1187.
136. Weber SM, Jarnagin WR, Klimstra D et al. Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001;193:384-391.
137. Casavilla FA, Marsh JW, Iwatsuki S et al. Hepatic resection and transplantation for peripheral Cholangiocarcinoma. J Am Coll Surg 1997;185:429-436.
138. Shimada M, Yamashita Y, Aishima S et al. Value of lymph node dissection during resection of intrahepatic Cholangiocarcinoma. Br J Surg 2001;88:1463-1466.
139. Ohtsuka M, Ito H, Kimura F et al. Results of surgical treatment for intrahepatic Cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002;89:1525-1531.
140. Kitagawa Y, Nagino M, Kamiya J et al. Lymph node metastasis from hilar Cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001;233:385-392.
141. Pichlmayr R, Lamesch P, Weimann A et al. Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83-88.